Claude LAURENS’ Post

Importance of patient preferences should guide every stakeholder to develop products that answer patients ‘ needs and help regulatory in their decion making process

Pleural effusion (PE) lymphocytes: are PD-1/PD-L1 and IL-10/IL-10R cellular expressions lower on T-cells in malignant PE rather than benign PE ones? A study by Mosleh, B., et al. investigated their role in the pathogenesis of PE regardless of the underlying disease. Read: https://buff.ly/3Nj2yXX #PE #T-cell #immunoediting #immunoescape #PD-1 #PD-L1 #IL-10 #IL-10R

Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions https://lnkd.in/giDHRaDq

Clinical Trials of LBS-007: In 2023, health authorities in both Australia and Taiwan approved the use of LBS-007 in clinical phase I/II trial for acute myeloid leukemia (AML). The ongoing trial in Australia focuses on the safety, tolerability, and finding optimal dosage of LBS-007. We are optimistic about the potential of LBS-007 as a next-generation, highly effective targeted therapy for AML treatment, offering commitment for improving patient survival. Read more about the LBS-007 clinical trial at： https://lnkd.in/g6yUKTy4 #linbioscience #lbs007 #clinicaltrials #acutemyeloidleukemia #TargetedTherapy

#Myelodysplastic syndromes (MDS) are a diverse group of #cancers that result in #bonemarrow failure and may develop into more advanced cancers such as acute myeloid #leukemia. In ongoing clinical trials, YSM researchers are investigating new therapies that could offer MDS patients independence from #transfusions. https://brnw.ch/21wGi9A

Insights from my talk at the #HeartFailure2024 titled “A case of an acute fulminant myocarditis-induced cardiogenic shock with biopsy-evident massive CD3+ T and CD20+ B lymphocytic infiltrates and detection of B19V- and EBV-genome”

Here is a definition of palliative sedation according to the National Cancer Institute: “The use of special drugs called sedatives to relieve extreme suffering by making a patient calm, unaware, or unconscious. This may be done for patients who have symptoms that cannot be controlled with other treatment. Palliative sedation may be used in patients who are near the end of life to make them more comfortable. It is not meant to shorten life or cause death.” I make a brief mention of palliative sedation in my “Hard Choices” book in the section on pain control. Here is the link to Amazon for “Hard Choices”: https://lnkd.in/eYftDAmp

The acute lymphoblastic #leukemia experts analyze the sequencing of CAR T-cell therapy for pts w/ & w/o prior blinatumomab exposure, addressing potential concerns associated w/ using blinatumomab before CAR T treatment. https://lnkd.in/eGij6Z5M

Today is World CML Day , 22nd of September. Chronic Myeloid Leukemia (CML) is a type of leukemia that we’re grateful to now control due to advancements in science and research. Today, patients can live with a normal life expectancy due to revolutionary treatments that began in the year 2000. The introduction of daily oral medications transformed the way CML is managed, allowing patients to live healthy and active lives. Ongoing research continues to improve treatment options, focusing on enhancing both the quality of life and clinical outcomes for those living with CML. CML symptoms can take time to appear and may include fatigue, weight loss, or abdominal discomfort. However, it is often detected through elevated white blood cell (WBC) counts in a routine Complete Blood Count (CBC). If this is the case, a hematologist will conduct further tests to confirm the diagnosis. #WorldCMLDay

ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia